 ~ unlocking the mysteries of HIV treatment ~ |
| ENROLLING
HIV TREATMENT
STUDIES en espaņol |
IF YOU HAVE NOT TAKEN ANTI-HIV MEDICATION:
(TREATMENT NAĪVE) |
| ACTG 5095: | A study comparing three simple drug combinations for HIV treatment.
- Protease Inhibitor-Sparing Initial Treatment of HIV Infection
- Viral load over 400
- No prior anti-HIV therapy
|
Study Treatment Regimen
Step 1 (randomized):
Trizivir* + Sustiva (efavirenz)
Combivir* + Sustiva (efavirenz) | Step 2 (if virologic failure occurs):
2 Nucleosides + Sustiva (efavirenz) or
Trizivir*
2 Nucleosides + atazanavir |
| HIV TREATMENT VACCINES |
| Merck 006: | HIV vaccine treatment study.
- Taking anti-HIV medication for at least 1 year
- Viral load less than 500, T-cell less than 500
- No history of T-cells less than 200 for at least 1 year
|
|
IF YOU HAVE TAKEN ANTI-HIV MEDICATION:
(TREATMENT EXPERIENCED) |
| ACTG 5086: | Can resistance testing and temporarily stopping treatment be helpful for people who have already taken anti-HIV medications?
- Structured Treatment Interruption (STI) in Salvage Therapy
- T-cell count over 150
- Viral over 10,000 on current HAART regimen AND extensive exposure to all 3 drug classes
- Randomized to STI of up to 16 weeks vs. immediate initiation
of salvage regimen based on resistance testing (both genotype and
phenotype provided real time)
|
| Shionogi S-1360: | A study that looks at a new way to fight HIV and decrease viral load.
- Integrase Inhibitor - a drug that keeps HIV from inserting its DNA into the T-cell DNA
- Off medication for 4 weeks
- Viral load over 5,000, T-cells over 100
- Requires 2 overnight stays in the hospital, compensation provided
|
HIV AND OPPORTUNISTIC INFECTIONS:
(INCLUDING COMPLICATIONS AND SIDE EFFECTS) |
| ACTG 5030: | Can CMV disease be prevented? Free eye exam provided.
- Pre-emptive Treatment for CMV Viremia using Oral Valganciclovir
- Viral load over 400, T-cells less than 100
- Presence of CMV IgG antibodies
- HAART continuously for greater than 3 months -OR- not planning to initiate HAART for 3 months after entering study
- Subjects developing CMV viremia randomized to valganciclovir vs. placebo
- (Assess CMV viral load level - provided real time)
|
 For more information, please call 746-4177 or 746-7206 and ask to speak to a Research Nurse. |
Cornell Clinical Trials Unit
|